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A B S T R A C T
With the progression towards personalised and age-appropriate medicines, the production of drug loaded li-
posomes at the point of care would be highly desirable. In particular, liposomal solubilisation agents that can be
produced rapidly and easily would provide a new option in personalised medicines. Such a process could also be
used as a rapid tool for the formulation and pre-clinical screening of low soluble drugs. Within this paper, we
outline a novel easy-to-use production method for point of use production of liposome solubilised drugs. Our
results demonstrate that pre-formed multilamellar liposomes, stored in a fresh or frozen format, can be bilayer
loaded with low solubility drugs using a simple bath sonication process. Sonication is undertaken in a sealed vial
allowing the contents to remain sterile. Liposomes around 100 nm were prepared and these liposomes were able
to increase the amount of drug dissolved by up to 10 fold. These liposomal solubilisation agents were stable in
terms of size and drug solubilisation for up to 8 days when stored in the fridge making them an easy to use and
robust small-scale tool for drug solubilisation.
1. Introduction
Both the pre-clinical development and clinical use of many drugs
remains hindered by their low solubility. Indeed, the ability to produce
medicines in a liquid format remains a major consideration in pediatric
and childrens medicines. Liquid dosage forms can also oﬀer advantages
as age-appropriate formulations, they oﬀer ﬂexibility in dosing and
provide wider options for those who suﬀer from dysphagia. Tablets in
particular can cause issues for pediatric dosing; for example, the World
Health Organization noted that 4 children under 36 months in age died
due to choking in a deworming campaign in Ethiopia during 2007
(WHO, 2007). They also noted that medical personnel are having to
either break up tablets, dissolve them in solvents, or administer the
powder contained in a capsule to young children as a relevant liquid
drug delivery system isnt available for that drug. However, there are a
number of risks associated with these methods including diﬃculties in
splitting and dividing of tablet doses and ensuring the drug can be re-
constituted in water in a homogeneous system. Therefore, new solu-
tions for such medicines are needed to overcome these issues.
Similar issues are faced with low solubility drugs in early pre-clin-
ical development. Therefore a standard solubilizing agent that can be
adopted for poorly soluble active pharmaceutical ingredients at a range
of concentrations, that avoids the use of solvents, and that is non-toxic
and easy to use would accelerate preclinical formulation time-lines.
There are a number of diﬀerent techniques used for formatting low
solubility drugs, and suspension formulations are commonly used in the
early discovery phase, owing to their ease of preparation. However,
disadvantages associated with these systems can include batch-to-batch
variability (including particle size) and stability issues.
Liposomes have been extensively investigated for the delivery of
both hydrophobic and hydrophilic drugs due to their hydrophilic core
and hydrophobic bilayer structure (Gregoriadis and Perrie, 2010).
However, despite these advantages, their wide-scale use as clinically
approved products remains limited to a small number of high-cost
products: a key issue that has hindered their application is their cost-
eﬀective manufacture. As a result, the application of liposomes as so-
lubilisation agents is generally cost-prohibitive. Yet liposomes oﬀer the
potential to act as solubilisation agents in a range of applications, in-
cluding point-of-care medicine manipulation and point-of-use pre-
clinical studies. For example, in early work from our group
(Mohammed et al., 2004), we were able to load ibuprofen into the li-
posome bilayer and use liposomes as a lipophilic drug carrier. These
studies identiﬁed key factors to consider in the formulation of liposomal
solubilising agents. This included cholesterol bilayer content, lipid alkyl
length and the presence of charged lipid head-groups (Mohammed
et al., 2004). Following on from this, we considered a range of drugs
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(propofol, ibuprofen, phenytoin, diazepam and midazolam and ri-
fampicin) and demonstrated that fatty alcohols could be used as bilayer
stabilisers as an alternative to cholesterol (Ali et al., 2013). This work
also showed that drug molecular weight is a key factor inﬂuencing drug
loading within liposomes bilayers, with the larger molecules such as
rifampicin showing low drug bilayer loading compared to smaller
molecules such as propofol and ibuprofen (Ali et al., 2010; 2013). Kaess
and Fahr (2014) has also shown that by taking advantage of the in-
creased lipophilic relative area aﬀorded to small liposomes compared to
larger ones, they were able to load temoporphin into a number of dif-
ferent liposomal formulations.
Thus, whilst liposomes oﬀer the potential to act as solubilisation
agents, there remains a lack of appropriate, rapid and cost-eﬀective
production methods to allow the use of liposomes as solubilisation
agents. Formation of large vesicles followed by size-reduction via so-
nication is a well-established method for the production of small-uni-
lamellar liposomes in the laboratory setting. Yet this method is gen-
erally not suitable for the production of liposomes beyond the
laboratory due to its multi-step process and lack of scalability.
Sonication is a commonly used small-scale tool for size reduction and
can be split into two options; bath and probe sonication. Probe soni-
cation is the usual method employed due to its ease of use. It is also a
well characterized and rapid method (e.g. Lapinski et al., 2007; Paini
et al., 2015; Mendez and Banerjee, 2017). However, it can be limited by
a lack of temperature control and the need to remove contamination
post sonication (e.g. titanium particles that have sheared oﬀ the probe
(Philippot et al., 1994)). Furthermore, this method cannot be conducted
under sterile conditions due to the contact required between the sample
and the probe. In contrast, bath sonication, can be conducted under
sterile conditions (Lasic, 1998) and oﬀers the opportunity to produce
liposomes solubilizing drug at the individualized patient scale. It also
oﬀers the ability to work with low levels of active pharmaceutical in-
gredient, as is often the case in early formulation studies. Therefore,
given that there is a need for the rapid and simple formulation of low
solubility drugs, the aim of this current study was to develop a simple
and rapid method for producing liposome solubilized drug formulations
in a point of use setting. Our objectives were to investigate if drugs
could be solubilized into pre-formed liposomes via sonication and the
impact of drug and lipid selection had on this process.
2. Materials and methods
2.1. Materials
Ibuprofen, midazolam, propofol and cholesterol were purchased
from Sigma-Aldrich, Dorset, UK. 1,2-distearoyl-sn-glycero-3-phos-
phocholine (DSPC), 1,2-distearoyl-sn-glycero-3-phospho-(1-rac-gly-
cerol) (DSPG), were obtained from Avanti Polar Lipids, Alabama. All
chemicals used were of analytical grade and were used without further
modiﬁcation.
2.2. Methods
2.2.1. Preparation of multilamellar vesicles
MLV were generated using a technique based on the established ﬁlm
method and modiﬁed for low solubility drugs. Brieﬂy the lipid entities
were dissolved in a chloroform:methanol (9:1) at appropriate ratios and
the solvent evaporated on a rotary evaporator to yield a dry ﬁlm as per
the standard lipid ﬁlm hydration method. To entrap drugs within the
bilayer, the required amount of drug was added to the solvent mixture
and subsequently hydrated. Liposomes were formed from DSPC:Chol;
4:1 M ratio, or DSPC:Chol:DSPG; 6:4:2.5 M ratio. In all cases, the ﬁlm
was hydrated with 2mL of phosphate buﬀer saline (PBS) to give ﬁnal
lipid concentration of 2mg/mL unless otherwise stated.
2.2.2. Preparation of small unilamellar vesicles
To prepare small unilamellar vesicles (SUV), 1 mL of MLV were
subjected to sonication for 15 sonication cycles (90 s/cycles) with 30 s
stop time between each sonication cycle using a Bioruptor® Plus soni-
cator at 40 °C. Using this system we are able to uniformly sonicates
multiple samples (312 samples) of volume from 100 uL to 20mL in
sealed tubes. This system uses ultrasounds derived from magnets placed
below the water tank and indirectly transfers ultrasonic energy to
samples. The control of the temperature and the distribution of the
energy inside the water bath and the continuous rotation of tubes
promoted even sonication of samples. Each of the 3 diﬀerent drugs were
added independently to liposomes using 3 diﬀerent options; option 1:
drug was added during MLV preparation followed by sonication; option
2: drug was added post MLV formation but prior sonication; and option
3: drug was added to pre-made SUV and subjected to sonication
(Fig. 1).
Fig. 1. Method overview. Schematic re-
presentation of the three processes tested for
promoting liposome-bilayer drug loading in
a rapid small-scale format.
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2.2.3. Determination of drug loading in liposomes
Liposomes loaded with drug were subjected to dialysis against PBS
for 3 h using dialysis membrane (MWCO: 1214 kDa) to remove un-
loaded drug from liposomes. After dialysis, loaded liposomes were
dissolved in methanol and analysed using UV-HPLC (Thermo Scientiﬁc,
UK) to calculate drug loading at the appropriate wavelength for each
compound (Ibuprofen, 221 nm; Midazolam, 258 nm and Propofol,
268 nm). A Luna 5 μ C18, 150mm×4.6mm 100 A, phenomenex
column was used to for HPLC separation using 0.1% TFA in water and
methanol as mobile phase. Standard calibration curves of drug were
used to calculate drug content in liposomes.
2.2.4. Determination of particle size, polydispersity and zeta potential
The z-average diameter and polydispersity (PDI) of liposomes was
determined by dynamic light scattering using the photon correlation
spectroscopy (PCS) technique measured on a Malvern Zetasizer Nano-
ZS (Malvern Instruments Ltd., UK). Using the cuvettes supplied by
Malvern, 100 μL of the sample was diluted by the hydration phase (e.g.
PBS buﬀer solution) up to 1mL and the vesicle size and PDI was
measured at 25 °C. The zeta potential of the liposomes was measured on
Malvern Zetasizer Nano-ZS (Malvern Instruments Ltd., UK) at 25 °C. To
measure the zeta potential 100 μL of liposome suspension was diluted in
900 μL of its aqueous phase (1:300 v/v PBS).
2.2.5. Liposome stability studies
Liposomal size, PDI, zeta potential and drug retention were used as
parameters to indicate the physical stability of liposomes. The stability
of formulations, with respect to retention of the entrapped drug and
changes in the size distribution, were determined by incubating vesicles
(after separation of the free drug) in PBS at 48 °C. Initially, three in-
dependent samples of drug loaded liposomes were prepared for each
time intervals. Immediately after preparation, and at time intervals of
24, 48, 96 and 192 h, samples were analysed.
3. Results
3.1. Sonication of pre-formed MLV in the presence of drug can promote
eﬀective drug solubilisation in a sterile and easy to use method
The objective of this work was to investigate three diﬀerent
methods for the loading of lipophilic drugs using the bath sonicator, as
outlined in Fig. 1. Three options were considered; option 1 involves the
traditional lipid ﬁlm hydration method with the drug added at the in-
itial stage of the lipid ﬁlm formation. This method is generally re-
stricted to a laboratory setting. In Option 2 the drug is mixed with
preformed multilamellar vesicles (MLV) and subjected to sonication.
This would allow pre-formed MLV to be prepared within appropriate
manufacturing facilities and then a rapid 1 step-process to convert these
liposomes into drug loaded small unilamellar vesicles (SUV). In option
3, the drug is mixed with preformed SUV and subject to sonication to
promote drug solubilisation. Our liposomes were formed from DSPC
and cholesterol based on previous studies we had undertaken with li-
posomes as drug solubilizing agents, where we show that longer alkyl
chain length lipids promote higher bilayer loading (Mohammed et al.,
2004). Cholesterol content was also shown to impact on bilayer
loading, with the presence of cholesterol promoting liposome stability
yet hindering bilayer drug loading and therefore a DSPC:Chol lipid
weight ratio of 10:4 was selected to meet the needs of both good li-
posome stability and bilayer drug loading.
3.1.1. Sonication protocol optimization
To develop a rapid point-of-use process for the production of lipo-
some-solubilised drug, initially the sonication process was optimised
(Fig. 2). Using 15 sonication cycles of 90 ss/cycle produced liposomes
100120 nm in size with PDI of 0.2 and a single particle size population
were prepared (Fig. 2A and B). The eﬀect of lipid concentration on
particle size reduction was also investigated (Fig. 2C). Lipid con-
centrations between 1 and 10mg/mL were all eﬀectively reduced to
vesicle sizes between 100 and 120 nm with PDI of 0.2 demonstrating
that a wide range of lipid concentrations could be eﬀectively size re-
duced using the same sonication protocol. Lower lipid concentrations
(0.5 mg/mL) tended to give slightly higher and more variable size
ranges (120160 nm) but again with a PDI range of 0.2 (Fig. 2C).
3.1.2. Selection of drug loading process
To consider drug loading, three options were considered as outlined
in Fig. 1. In all three options, the liposomes were sonicated for 15 cycles
as shown in Fig. 2. As can be seen in Fig. 3, both option 1 and 2 gave
similar vesicle sizes and PDI across the three drugs tested (particle sizes
100140 nm, PDI 0.2; Fig. 3) with neither the point of addition of the
drug into the liposomes nor the drug loaded having an impact. How-
ever, in the case of pre-formed SUV mixed with drug and subjected to
sonication, there was some variability in size and PDI particularly in the
case of propofol with sizes increasing to 250 nm (Fig. 3B) which may be
a results of over sonication and stress damage to the lipids which can
promote aggregation.
In terms of drug loading within the liposomes, results in Fig. 3 are
Fig. 2. The eﬀect of sonication cycles on liposome particle size attributes. Liposome
(DSPC:Chol; 4:1M ratio, 2 mg/mL) size and polydispersity (A) and intensity plots (B) of
vesicles subjected to 15 sonication cycles (90 ss/cycle). The eﬀect of lipid concentration
on particle size and PDI (C) was also measured. Results represent mean ± SD, for 3
independent experiments.
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presented as % drug loading, drug loading as μg/mL, and as mol% as
drug solubilisation is reported in these various ways. The results in
Fig. 3 show that for all three drugs, addition of the drug during the
formation of MLV (option 1) gives the highest drug loading (23%, 30%
and 7% for ibuprofen, propofol and midazolam; Fig. 3AC respec-
tively). Mixing of drug with pre-formed MLV followed by sonication
gives the second highest level of drug loading (option 2; 12%, 23% and
5% for ibuprofen, propofol and midazolam respectively; Fig. 3). Finally
option 3 (mixing drug with pre-formed SUV followed by sonication) is
the least eﬃcient method for promoting bilayer loading (3%, 12% and
2% for ibuprofen, propofol and midazolam respectively; Fig. 3). When
comparing between the drugs, propofol was shown to give the highest
drug loading in all three options, in line with our previous studies using
MLV (Ali et al., 2013).
To consider the stability of the liposome-solubilized drug systems,
liposomes prepared by all three loading methods, with the three drugs
loaded, were subjected to a short-term stability study. Liposomes were
stored at 28 °C for up to 192 h to investigate the potential of storing
these systems in the fridge in line with extemporaneously prepared oral
suspensions which can be stored for 1 week. The results in Fig. 4 de-
monstrate that drug-loaded liposomes formulated by option 1 or 2 were
stable over the test period, maintaining their size and retaining their
drug loading for all three drugs tested. When pre-loaded SUV were
sonication-loaded with drug, there was some initial variability in ve-
sicle size and reductions in the already low drug loading were noted
over time. From the results in Figs. 3 and 4, option 1 gave the highest
drug loading; however, option 2 oﬀers both appropriate drug loading in
combination with an easy to use process that could be adopted in a
range of environments using pre-manufactured MLV solutions.
3.1.3. Liposome solubilisation capacity
To consider the solubilisation capacity, liposomes at a concentration
of 2mg/mL (total lipid) were loaded with propofol over a range of
concentration (15mg/mL) using option 2. The results in Fig. 5 de-
monstrate that % drug loading remained at 2325% across the con-
centrations used and resulted in absolute drug loading increasing up to
1250 ug/mL (Fig. 5A and B respectively). However, at increasing pro-
pofol concentrations, vesicle size was shown to increase from 110 to
170 nm, with a corresponding increase in PDI to 0.26 at 5mg/mL
propofol (Fig. 5C and D). Therefore depending on the application, the
lipid:drug ratio should be considered, as this is often a key critical at-
tribute of a liposomal formulation.
Fig. 3. Drug bilayer loading via sonication. Three methods of formulating liposomes (DSPC:Chol; 4:1 M ratio, 2 mg/mL) were tested; liposomes were prepared by lipid hydration and drug
loading was achieved as outlined in Fig. 1. Particle size, PDI and drug loading via the three diﬀerent methods for ibuprofen, propofol and midazolam are shown in A, B and C respectively.
Results represent mean ± SD, for 3 independent experiments.
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3.2. Liposomal-solubilised drugs can be rapidly prepared using pre-formed
and frozen liposomes
To consider the potential of using pre-manufactured MLV stored in a
frozen format (thereby potentially increasing their long-term storage
stability), a batch of MLV liposomes prepared at the usual 2mg/mL
were prepared, and stored frozen for up to 28 days. These liposomes
were then defrosted and used to prepare liposomal solubilisation as per
option 2. The results show that frozen MLV stocks were as eﬀective as
freshly prepared MLV in terms of propofol loading and vesicle size
(Fig. 6), demonstrating that pre-manufactured liposomes could be
shipped/stored in a frozen format prior to use to extend their long term
Fig. 4. Short-term stability of liposomes. Liposomes (DSPC:Chol; 4:1M ratio, 2mg/mL) were prepared and loaded with either ibuprofen, propofol or midazolam by the three methods
(option 1: A and D; option 2: B and E; option 3: C and F) and stored at 28 °C. Drug loading (A, B, C) and particle size (C, D, E) were measured at time intervals. Results represent
mean ± SD, for 3 independent experiments.
Fig. 5. Eﬀect of initial drug concentration in terms of propofol loading (% loading (A), μg/mL (B)), particle size (C) and PDI (D). Liposomes composed of (DSPC:Chol; 4:1M ratio, 2 mg/
mL) were prepared with increasing propofol concentrations from 15mg/mL. Results represent mean ± SD, for 3 independent experiments.
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stability Table 1.
3.3. Incorporation of anionic lipids enhances drug solubilisation capacity
The liposomes used in Figs. 26 were formulated from a simple
DSPC:Cholesterol (4:1M ratio) formulation. This was based on early
studies demonstrating that low levels of cholesterol were able to sta-
bilize the vesicles without inhibiting bilayer drug loading (Mohammed
et al., 2004). However, the addition of charged lipids is commonly used
to enhance liposome stability and may impact on bilayer drug loading.
Therefore, we also investigated an anionic liposome formulation in-
corporating DSPG, as PG lipids are used within several commercially
available liposome products. Following sonication, empty liposomes
were 100120 nm in size, similar to DSPC:Chol liposomes. In terms of
propofol drug loading, this was higher for the anionic liposome for-
mulation for all three methods of manufacture (Fig. 7A) when com-
pared to DSPC:Chol liposomes (Fig. 2) with the anionic liposomes
giving 40% propofol loading (1mg/mL initial amount added). These
liposomes were stable over 8 days, similar to the neutral DSPC:Chol
liposomes (Fig. 7BE). Again these results show that loading drug
within pre-formed MLV is a rapid and convenient option for producing
liposomal-solubilised drug. Similarly, pre-formed and frozen MLV can
be used in this process to produce liposome-solubilised drug rapidly
(Table 2) which oﬀers an easy way to store such pre-formed liposomes
for longer periods. This also oﬀers the options of larger batches of MLV
to be prepared, aliquoted and stored ready for use.
In Figs. 37, the results are shown as drug solubilized within the
liposome bilayers (with non-entrapped drug being removed). This
would be appropriate for drug delivery options where the bilayer-
loaded drug distribution is to be dictated by the liposomes, as in the
case of Ambisome® for example. Liposomes are well recognized for
their ability to passively target either the mononuclear phagocytic
system, sites of inﬂammation and/or tumour sites depending on their
structural design (Gregoriadis and Perrie, 2010). When considering
their capacity as solubilizing agents, where it is total drug dissolved that
is the key, the overall enhanced solubility oﬀered by employing lipo-
somes is shown in Fig. 8. Here we show the total amount of drug in
solution (i.e. free dissolved drug is not removed from the liposome
suspension); both the DSPC:Chol and DSPC:Chol:DSPG liposomes oﬀer
around a 10 fold increase of drug in solution (Fig. 8).
4. Discussion
There are many options available to improve the solubility of drugs
including pH and salt forms, co-solvents and micelle solubilisation,
solid dispersions and co-crystals, inclusion complexation,
Fig. 6. Stability of liposomal-drug formulations prepared from frozen MLV. MLVs were stored at−20 °C for 1, 4, 7, 18 and 28 days. After thawing, drug was added via option 2 (Fig. 1)
with liposomes sonicated for 15 sonication cycles (90 ss/cycle). Drug loading (A and B), particle size (C) and PDI (D) is shown respectively. Results represent mean ± SD, for 3
independent experiments.
Table 1
Attributes of drugs solubilised within liposomes.
Drug Structure Molecular
weight (Da)
Water
solubility
mg/mL at
25 °C
log P pKa
Propofol 178 0.124 3.79 11.1
Ibuprofen 206 0.021 3.97 4.9
Midazolam 326 0.024 4.33 5.5
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emulsiﬁcation and nanotechnologies. Each of these systems oﬀers a
range of advantages and disadvantages. In the case of liposomes, they
oﬀer the ability to improve solubility without the use of co-solvents and
are stable upon dilution. Liposomes can also protect the drug from
degradation and can be designed to dictate the drug biodistribution.
Liposomes can be produced using lipids that are relatively low cost and
they have a proven track-record clinically. However, the use of lipo-
somes is limited by their complex manufacturing processes. In many of
these methods we rely on size reduction of large vesicles. In the la-
boratory setting this normally starts with the lipid ﬁlm hydration
method. To reduce vesicle sizes, a range of methods can be adopted
including sonication, shear or pressure forces, including micro-
ﬂuidization, high-pressure homogenization or other shear force-in-
duced homogenizer to reduce vesicle size (Wagner and Vorauer-Uhl,
2011; Szoka and Papahadjopoulos, 1980).
To support their more accessible use and provide a rapid low-cost
solubilisation tool, we have developed a novel and simple small-scale
drug loading method has been developed. Sonication is a well-re-
cognized tool for size reduction of liposomes with some of the ﬁrst li-
posomal studies employing this method (e.g. Papahadjopoulos and
Miller, 1967; Papahadjopoulos and Watkins, 1967). Probe sonication is
a cheap, simple and heavily used method but is limited by potential
lipid degradation resulting from overheating (Uchegbu, 2013; Lapinski
et al., 2007). In contrast, bath sonication is a non-contact option that
can be temperature controlled. Previously studies by Lapinski et al.,
2007 using rotational and translational diﬀusion of an embedded
chromophore have shown that liposomes formed by bath sonication
and extrusion exhibit the same molecular scale environment despite
diﬀerences in size. Indeed, the molecular scale organization is de-
termined by lipid interactions. Therefore, there is the potential that a
Fig. 7. Propofol loaded into anionic liposome formulations. Three methods of formulating liposomes (DSPC:Chol:DSPG; 6:4:2.5 M ratio, 2 mg/mL) were tested. Particle size, PDI and drug
loading via the three diﬀerent methods for propofol are shown in A. Short term stability at 28° for up to 192 h via the three diﬀerent methods for propofol was also measured and particle
size (B), PDI (C), drug loading (D) and zeta potential (E) are shown respectively. Results represent mean ± SD, for 3 independent experiments.
Table 2
Drug solubilisation within freshly prepared and frozen anionic liposomes. Anionic MLV (DSPC:Chol:DSPG; 6:4:2.5M ratio, 2mg/mL) were stored at−20 °C for 24 h. After thawing, drug
was added via sonicated for 15 sonication cycles (90 ss/cycle). Results represent mean ± SD, for 3 independent experiments.
Initial stocks Physicochemical characterisation of resultant SUV Propofol loading
Size (nm) PDI ZP (mV) % loading μg/mL Mol%
Freshly prepared MLV 138.5 ± 2.3 0.16 ± 0.01 −52.7 ± 4.2 40 ± 1 408 ± 17 51 ± 0.2
Frozen MLV 126.3 ± 6.5 0.19 ± 0.01 −54.0 ± 8.6 47 ± 1 470 ± 7 48 ± 0.4
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similar protocol exploiting extrusion, rather than sonication, could
achieve similar results. However, extrusion on a small scale can be la-
borious and is more cost eﬀective at larger scales. Therefore, the po-
tential of the low cost bath sonication protocol to maintain a closed
sterile formulation under controlled temperature conditions and have a
set programme with minimal user input oﬀers key advantages.
Obviously, in addition to their ability to improve drug solubility,
liposomes can be used to control the delivery of drugs, with around 15
liposome products currently licensed for this use. With many of these
products, active loading is used for optimized loading of ionizable drugs
and this is measured by drug-to-lipid ratios as this ratio often impacts
on stability and drug release rates (Modi et al., 2012). However, the
extremely low aqueous solubilities of many drug candidates can limit
the external driving force, thus slowing liposomal uptake during active
loading (Modi et al., 2012) and therefore can limit its application in
small scale batches with low solubility drugs. Whilst the above bath-
sonication platform technology can also be applied for drug delivery
systems, this method is not appropriate for aqueous soluble drugs and
an additional step to remove non-incorporated drug is required if
considered for in vivo use parenterally. There are also the various
quality control and quality assurance aspects that would need to be
considered for point-of-care production of any medicine. However, for
bilayer loaded drugs, this method can be used for not only enhance
solubility but can enhance potency. This can make it a useful tool for
pre-clinical studies. For example, work by Pandelidou et al (2011) de-
monstrated that the incorporation of curcumin within eﬀ PC liposomes
with high eﬃciency (85% when at a drug to lipid molar ratio of 1:14)
and that the cytotoxicity against colorectal cancer cell lines was en-
hanced.
5. Conclusions
These studies were designed to challenge the dogma that liposomes
cannot be easily prepared in a point-of-use setting. Here we show that
liposomes could be manufactured and shipped/stored as multi-lamellar
vesicles, then low-solubility drugs loaded into these liposomes at the
point of use to enhance solubility using a rapid and easy to use single-
sonication step. Whilst bath-sonication is a commonly used method, its
use as a single step drug loading method has thus far not been reported.
This new protocol can easily be adopted in pre-clinical studies in vitro
and in vivo (with an additional non-incorporated drug removal step if
administrated parenterally). This is particularly useful when API
amounts are often limited. This protocol also oﬀers the potential of
preparing personalized liquid dosage formats which can overcome is-
sues related to solid dosage forms.
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Fig. 8. Comparison of drug solubility with
and without A) neutral liposomes and B)
anionic liposomes present. Drug was sub-
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centrifuged for 1 h at 20,000 g and ﬁltered
through 0.22 um syringe ﬁlter. Results re-
present mean ± SD, for 3 independent ex-
periments.
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